MOTYS™  »  Preclinical  »  Clinical  »  Pipeline

Pipeline

Significant opportunity for indication expansion

Preclinical evidence provides proof-of-concept in a range of highly prevalent musculoskeletal degenerative conditions.

Contact Us

Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.